FIELD: medicine.
SUBSTANCE: invention relates to a solid form of N-[(3-fluoro-4-methoxypyridine-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridine-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide, which shows at least following characteristic peaks of X-ray powder diffraction (Kα-radiation Cu expressed in degrees 2θ) approximately at 11.2, 12.5, 13.2, 14.5 and 16.3, and to a solid form of sulfate of N-[(3-fluoro-4-methoxypyridine-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridine-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide, which shows at least following characteristic peaks of X-ray powder diffraction (Kα-radiation Cu expressed in degrees 2θ) approximately at 5.1, 7.5, 12.0, 15.2 and 17.9. the invention also relates to a pharmaceutical composition intended for the treatment of diseases or pathological conditions mediated with plasma kallikrein based on the specified forms.
EFFECT: technical result is that new solid forms of N-[(3-fluoro-4-methoxypyridine-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridine-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and pharmaceutical composition based on them are obtained, which can be used in medicine for the treatment of diseases or pathological conditions mediated with plasma kallikrein.
25 cl, 47 dwg, 21 tbl, 27 ex
| Title | Year | Author | Number |
|---|---|---|---|
| N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDE COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | 2015 |
|
RU2707870C2 |
| N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDE COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | 2015 |
|
RU2821520C2 |
| PYRAZOLE DERIVATIVES AS KALLIKREIN INHIBITORS | 2017 |
|
RU2739447C2 |
| METHOD FOR PRODUCTION OF NEW CRYSTALLINE FORMS OF 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDOPYRIDIN-4-YL)-5-METHOXYPYRIDINE-2-CARBOXAMIDE AND ITS CRYSTALLINE FORMS | 2013 |
|
RU2621894C2 |
| NEW CRYSTALLINE FORM OF 2-{3-[2-(1-{[3,5-BIS(DIFLUOROMETHYL)-1H-PYRAZOL-1-YL]ACETYL}PIPERIDIN-4-YL)-1,3-THIAZOL-4-YL]-4,5-DIHYDRO-1,2-OXAZOL-5-YL}-3-CHLOROPHENYLMETHANE SULPHONATE | 2014 |
|
RU2691948C2 |
| CRYSTALLINE FORMS OF 1-[(3R,4S)-4-CYANOTETRAHYDROPYRAN-3-YL]-3-[(2-FLUORO-6-METHOXY-4-PYRIDYL)AMINO]PYRAZOLE-4-CARBOXAMIDE | 2019 |
|
RU2828229C2 |
| 4-METHYL-N-[3-4-METHYLIMIDAZOL-1-YL)-5-TRIFLUOROMETHYLPHENYL]-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)BENZAMIDE SALTS | 2006 |
|
RU2509767C1 |
| 4-METHYL-[3-(4-METHYLIMIDAZOL-1-YL)-5-TRIFLUOROMETHYLPHENYL]-3-(4-PYRIDIN-3-YLPYRIMIDIN-2-YLAMINO)BENZAMIDE SALTS | 2006 |
|
RU2434864C2 |
| 4-METHYL-N-[3-(4-METHYLIMIDAZOL-1-YL)-5-TRIFLUOROMETHYLPHENYL]-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)BENZAMIDE SALTS | 2006 |
|
RU2483065C2 |
| SALTS OF 4-METHYL-N-[3-(4-METHYLIMIDAZOLE-1-YL)-5-TRIFLUOROMETHYLPHENYL]-3-(4-PYRIDINE-3-YLPYRIMIDINE-2-YLAMINO)BENZAMIDE | 2013 |
|
RU2605551C2 |
